Standout Papers
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma (2000)
- Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline (2015)
- Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline (2015)
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study (2018)
Immediate Impact
7 by Nobel laureates 6 from Science/Nature 67 standout
Citing Papers
Nanomedicine Tumor Targeting
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Works of Mark R. Middleton being referenced
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound
2023
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mark R. Middleton | 7112 | 6072 | 2266 | 360 | 13.2k | |
| David R. Spriggs | 4808 | 4177 | 2929 | 229 | 12.8k | |
| Rosemarie Mick | 6092 | 3493 | 3164 | 262 | 14.1k | |
| Richard D. Carvajal | 7072 | 4660 | 3774 | 284 | 12.0k | |
| Anthony W. Tolcher | 7038 | 8671 | 1924 | 431 | 16.1k | |
| Ryan J. Sullivan | 9244 | 3856 | 3239 | 381 | 12.9k | |
| Steven T. Rosen | 5606 | 4378 | 3183 | 413 | 15.5k | |
| Douglas B. Johnson | 9445 | 4462 | 3922 | 289 | 13.5k | |
| Ulrich Keilholz | 9074 | 6046 | 5711 | 471 | 15.1k | |
| David G. Kirsch | 3980 | 5947 | 1136 | 257 | 13.0k | |
| Kevin Camphausen | 5166 | 5477 | 2517 | 321 | 14.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...